SiRNA compound that inhibits complement factor B (CFB)
Nucleic acid products that modulate, in particular interfere with or inhibit CFB gene expression, are provided. The products may be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion o 5 f RNA transcribed from a CFB gene, where the first nucleobase sequence is selected from SEQ ID NOs 1 to 391, 751 and 752, or a fragment thereof.
1 . An siRNA compound that inhibits complement factor B (CFB), comprising
(a) a first nucleobase sequence that is SEQ ID NO:251 linked directly to a second nucleobase sequence that is SEQ ID NO:503, or
(b) a first nucleobase sequence that is SEQ ID NO:252 linked directly to a second nucleobase sequence that is SEQ ID NO:504;
wherein said compound is 30 or 33 nucleosides long,
wherein optionally at least one sugar in the siRNA is modified, and
wherein optionally at least one internucleoside linkage is modified.
2 . The siRNA according to claim 1 , having the sequence of SEQ ID NO:755.
3 . The siRNA according to claim 1 , having the sequence of SEQ ID NO:756.
4 . The siRNA according to claim 1 , which further comprises one or more ligands, wherein said ligand optionally comprises at least one carbohydrate.
5 . The siRNA according to claim 4 , wherein said one or more carbohydrates comprise one or more N-Acetyl-Galactosamine moieties.
6 . The siRNA according to claim 1 , wherein sugars of the nucleosides at any of positions 2 and 14 downstream from the first nucleoside of the 5′ end do not contain 2′-O-methyl modifications.
7 . The siRNA according to claim 1 , wherein sugars of the nucleosides at any of positions 9 to 11 downstream from the first nucleoside of the 5′ end contain 2′-F modifications.
8 . A pharmaceutical composition comprising a compound according to claim 1 , and a physiologically acceptable excipient.
9 . A method of treating a disease or disorder, comprising administering to a subject suffering from said disorder an effective amount of a compound according to claim 1 , wherein said disease or disorder is selected from autoimmune disease, complement system dysfunction including aberrant upregulation of complement components such as CFB, age-related macular degeneration (AMD) including dry AMD and geographic atrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), Ig-mediated kidney pathologies such as IgA nephropathy and primary membranous nephropathy, asthma, rheumatic disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), anti-neutrophil cytoplasmic antibody (ANCA) vasculitis, antiphospholipid antibody syndrome (APS), glomerulonephritis, psoriasis, dermatomyositis bullous pemphigoid, Shiga toxin E. coli -related hemolytic uremic syndrome, myasthenia gravis (MG), neuromyelistis optica (NMO), dense deposit disease, C3 neuropathy, cold agglutinin disease, humoral and vascular transplant rejection, graft dysfunction, myocardial infarction, sensitization towards a transplant, and sepsis.